Pirfenidone: all 101 studies that test it

Page 1 of 2. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.

• Paricalcitol Versus Pirfenidone for Improving Surgical Resectability in Patients With Peritoneal CancerNot yet recruitingNCT07856914Phase 2
• Pirfenidone as Treatment of Chronic PancreatitisNot yet recruitingNCT07755813Phase 2
• A Phase I Evaluation of the Safety and Tolerability of Pirfenidone in Idiopathic Subglottic StenosisNot yet recruitingNCT07654517Phase 1
• Effect of Pirfenidone on TA FibrosisNot yet recruitingNCT07325357Phase 4
• Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07284602Phase 3
• Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug StudyRecruitingNCT06928272Phase 3
• Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal CarcinomaRecruitingNCT06484153Phase 2
• Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.RecruitingNCT06253117Phase 2
• Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell CarcinomaRecruitingNCT06142318Phase 2
• Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary FibrosisRecruitingNCT05842681Not applicable
• Prolonged Release Pirfenidone for Advanced Residual Liver Fibrosis (MINERVA).RecruitingNCT05542615Phase 2
• Efficacy and Safety of Pirfenidone in CTD-ILDRecruitingNCT05505409Phase 4
• Efficacy and Safety of Pirfenidone Capsules in the Treatment of PneumoconiosisRecruitingNCT05288179Phase 3
• Pirfenidone Use in Asbestosis Patients: Efficacy and PrognosisNot yet recruitingNCT05133453Not applicable
• Pirfenidone to Prevent Fibrosis in Ards.RecruitingNCT05075161Phase 3
• Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)RecruitingNCT03109288Phase 1/2
• A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the BloodCompletedNCT06070610Phase 1Results posted
• Safety and Tolerability of Pirfenidone in Acute PancreatitisCompletedNCT05350371Phase 1/2Results posted
• LYT-100 in Post-acute COVID-19 Respiratory DiseaseTerminatedNCT04652518Phase 2Results posted
• LYT-100 in Patients With BCRLTerminatedNCT04243837Phase 2Results posted
• Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)TerminatedNCT03473340Phase 2Results posted
• Pirfenidone for Restrictive Chronic Lung Allograft DysfunctionCompletedNCT03359863Phase 2Results posted
• Scleroderma Lung Study III - Combining Pirfenidone With MycophenolateCompletedNCT03221257Phase 2Results posted
• Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).CompletedNCT03208933Phase 3Results posted
• A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung DiseaseCompletedNCT03099187Phase 2Results posted
• Study of Efficacy and Safety of Pirfenidone in Patients With Fibrotic Hypersensitivity PneumonitisTerminatedNCT02958917Phase 2Results posted
• Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)CompletedNCT02808871Phase 2Results posted
• A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in CombinationCompletedNCT02606877Phase 4Results posted
• Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT02598193Phase 4Results posted
• Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPFCompletedNCT02579603Phase 4Results posted
• Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)CompletedNCT01933334Phase 2Results posted
• A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT01872689Phase 2Results posted
• Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT01366209Phase 3Results posted
• Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT00662038Phase 3Results posted
• Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary FibrosisCompletedNCT00287729Phase 3Results posted
• Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary FibrosisCompletedNCT00287716Phase 3Results posted
• Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary FibrosisCompletedNCT00080223Phase 2Results posted
• Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform NeurofibromasCompletedNCT00076102Phase 2Results posted
• Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)CompletedNCT00001959Phase 2Results posted
• Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak SyndromeCompletedNCT00001596Phase 2Results posted
• Study To Investigate The Potential DDI Between HEC585 And Pirfenidone/Nintedanib In Healthy SubjectsCompletedNCT07588646Phase 1
• PK of Deupirfenidone Versus Pirfenidone in Older Healthy SubjectsCompletedNCT07456800Phase 1
• Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy SubjectsCompletedNCT07229716Phase 1
• A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy ParticipantsCompletedNCT07015398Phase 1
• Silicone vs Pirfenidone in the Treatment of Hypertrophic Scars and KeloidsCompletedNCT06909812Phase 3
• Fibrosis-Modulating Effects of Metformin and Pirfenidone in Oral Submucous FibrosisCompletedNCT06871904Phase 1/2
• Prolonged Release Pirfenidone Versus Placebo in Compensated Cirrhosis.CompletedNCT06267794Phase 2
• A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodCompletedNCT06241560Phase 2
• Perfenidone in Type 2 Diabetic Patients With Diabetic NeuropathyCompletedNCT06224790Phase 4
• Pifenidone Prophylactic Therapy for Radiation Lung Injury in Patients Who Have Previously Received Immune Checkpoint InhibitorsCompletedNCT05801133Phase 2
• Pirfenidone in Adult Hospitalized Patients With COVID-19CompletedNCT05713292Phase 3
• Pirfenidone Treat Myocardial Fibrosis After Acute Myocardial InfarctionStatus unknownNCT05531955Phase 2
• To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy VolunteersCompletedNCT05383131Phase 1
• LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)Active, not recruitingNCT05321420Phase 2
• Pirfenidone Combined With Methylprednisolone Versus Methylprednisolone in the Treatment of CIPStatus unknownNCT05280873Phase 1
• Pirfenidone for the Reduction of Metabolic, Inflammatory and Fibrogenic Activity in Complicated SilicosisStatus unknownNCT05118256Phase 2
• Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy SubjectsCompletedNCT04971746Phase 1
• Dedicated Drug-Drug Interaction (DDI) Study in Healthy VolunteersCompletedNCT04939467Phase 1
• Immunosuppressant Combined With Pirfenidone in CTD-ILDActive, not recruitingNCT04928586Phase 4
• To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy VolunteersCompletedNCT04888715Phase 1
• Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 PneumoniaStatus unknownNCT04856111Phase 4
• Evaluation of the Efficacy of Pirfenidone in Progressive Chronic Hypersensitivity PneumonitisCompletedNCT04675619Phase 2
• Treatment With Pirfenidone for COVID-19 Related Severe ARDSCompletedNCT04653831Not applicable
• Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19Status unknownNCT04607928Phase 2
• Examination of Pirfenidone (Esbriet®) Therapy in Coal Workers' Pneumoconiosis With Pulmonary FibrosisCompletedNCT04461587Phase 2
• A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus InfectionStatus unknownNCT04282902Phase 3
• Trial of Pirfenidone to Prevent Progression in Chronic Kidney DiseaseStatus unknownNCT04258397Phase 2
• Efficacy and Safety of Pirfenidone Treatment in HPS-ILDStatus unknownNCT04193592Phase 2
• Pirfenidone Capsule in Patients With Chronic Kidney Disease G2 and G3a Study on Safety and PharmacokineticsStatus unknownNCT04126538Phase 1
• Pirfenidone and Advanced Liver Fibrosis.CompletedNCT04099407Phase 2
• A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy ParticipantsCompletedNCT03981094Phase 1
• Management of Progressive Disease in Idiopathic Pulmonary FibrosisCompletedNCT03939520Phase 4
• A Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury.CompletedNCT03902509Phase 2
• Efficacy and Safety of Pirfenidone in Patient With Dermatomyositis Interstitial Lung Disease (Dm-ILD)Status unknownNCT03857854Phase 3
• Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung DiseaseStatus unknownNCT03856853Phase 3
• Pirfenidone and Its Role in Burn Wound HealingCompletedNCT03530150Phase 2
• Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase AntibodiesCompletedNCT03385668Phase 2
• The Safety and Tolerability of Pirfenidone for BOS After HCTCompletedNCT03315741Phase 1
• Pirfenidone for Progressive Fibrotic SarcoidosisStatus unknownNCT03260556Phase 4
• Pirfenidone as Treatment of Skin Fibrosis in Systemic SclerosisStatus unknownNCT03068234Phase 2/3
• The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection FractionCompletedNCT02932566Phase 2
• Efficacy of Intralesional Triamcinolone and 8% Topical Pirfenidone for Treatment of Keloid ScarsStatus unknownNCT02823236Phase 3
• Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic DermatomyositisStatus unknownNCT02821689Phase 4
• Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic NephropathyCompletedNCT02689778Phase 3
• A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary FibrosisCompletedNCT02648048Phase 1
• Pirfenidone Effect on the Recovery of Renal Function in Septic Acute Kidney InjuryStatus unknownNCT02530359Phase 4
• A Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult ParticipantsCompletedNCT02525484Phase 1
• Pirfenidone in the Chronic Hypersensitivity Pneumonitis TreatmentStatus unknownNCT02496182Phase 2/3
• Utility of Prolonged-release Pirfenidone in the Progression of Chronic Kidney DiseaseCompletedNCT02408744Phase 1/2
• Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung InjuryStatus unknownNCT02296281Phase 2
• European Trial of Pirfenidone in BOS, A European Multi-center StudyCompletedNCT02262299Phase 2/3
• Effect of Topic Pirfenidone in Diabetic UlcersCompletedNCT02222376Phase 3
• Pirfenidone, an Antifibrotic and Antiinflammatory DrugCompletedNCT02161952Phase 2
• Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary FibrosisCompletedNCT02136992Phase 2
• Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF)Status unknownNCT01504334Phase 2
• Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1CompletedNCT00754780Phase 2
• Development of a Non-Invasive Treatment for Uterine Leiomyoma (Fibroids)CompletedNCT00332033Phase 2
• Pirfenidone: A New Drug to Treat Kidney Disease in Patients With DiabetesCompletedNCT00063583Phase 1/2
• Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform NeurofibromasCompletedNCT00053937Phase 1
• Pirfenidone in Treating Patients With Fibrosis Caused by Radiation Therapy for CancerCompletedNCT00020631Not applicable

← Pirfenidone overview